Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 12/20 | 0.51 |
| ▸ | AVPR1A | P37288 | 4/20 | 0.39 |
| ▸ | OXTR | P30559 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5110450 | 0.89 | AVPR2 (0.42) | AVPR2AVPR1A | |
| SCHEMBL5117110 | 0.89 | AVPR2 (0.47) | AVPR2AVPR1A | |
| SCHEMBL5785161 | 0.88 | AVPR2 (0.54) | AVPR2AVPR1AOXTRHPGDTSHR | |
| SCHEMBL5106699 | 0.85 | AVPR2 (0.49) | AVPR2AVPR1AOXTR | |
| SCHEMBL5784375 | 0.85 | AVPR2 (0.51) | AVPR2AVPR1AOXTR | |
| SCHEMBL5783050 | 0.84 | AVPR2 (0.50) | AVPR2AVPR1AOXTRKMT2A | |
| SCHEMBL6475968 | 0.83 | AVPR1A (0.40) | AVPR2AVPR1A | |
| SCHEMBL5784602 | 0.83 | AVPR2 (0.49) | AVPR2AVPR1AOXTRKMT2A | |
| SCHEMBL6210294 | 0.82 | AVPR1A (0.41) | AVPR2AVPR1A | |
| SCHEMBL5786497 | 0.81 | AVPR2 (0.48) | AVPR2AVPR1AOXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377585-B1 | NOVEL 10-CYCLOHEXENYL-PHENYL PYRROLOBENZODIAZEPINE-3-CARBOXAMIDES AND DERIVATIVES THEREOF; TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH CORP (US) | 2005-11-09 | — | — | EP | claimed |
| US-7326700-B2 | Cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists | WYETH (US) | 2008-02-05 | — | — | US | disclosed |
| EP-1377585-B1 | NOVEL 10-CYCLOHEXENYL-PHENYL PYRROLOBENZODIAZEPINE-3-CARBOXAMIDES AND DERIVATIVES THEREOF; TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH CORP (US) | 2005-11-09 | — | — | EP | disclosed |
| US-20030004159-A1 | Novel cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists | WYETH | 2003-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004159-A1 | Novel cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists | OXTR, OPRL1, HCRTR2 | AVPR2 38/4885AVPR1A 23/4885OXTR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.